Since NHE1 inhibitors play a cardioprotective role in IRI, cardiac hypertrophy, heart failure, and ventricular hypertrophy enhance vulnerability to IRI, NHE1 inhibitors may serve as a potential drug target in cardiac hypertrophy and heart failure. This evidence concerns the gene SLC9A1 and cardiac hypertrophy.